pioglitazone has been researched along with Right Ventricular Dysfunction in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Legchenko, E | 1 |
| Chouvarine, P | 1 |
| Borchert, P | 1 |
| Fernandez-Gonzalez, A | 1 |
| Snay, E | 1 |
| Meier, M | 1 |
| Maegel, L | 1 |
| Mitsialis, SA | 1 |
| Rog-Zielinska, EA | 1 |
| Kourembanas, S | 1 |
| Jonigk, D | 1 |
| Hansmann, G | 1 |
1 other study available for pioglitazone and Right Ventricular Dysfunction
| Article | Year |
|---|---|
PPARĪ³ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.
Topics: Fatty Acids; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Oxidation-R | 2018 |